6-Mercaptopurine vs Mycophenolate Mofetil in Autoimmune Hepatitis and Azathioprine Intolerance: A Multicenter Study
Clinical Gastroenterology and Hepatology · 2026-11 · 24 (11) · 3044-3054
DOI: 10.1016/j.cgh.2026.01.010 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-11. Verfasst von Ludwig Jesse Less-Horst und 22 weiteren Autor:innen. Beteiligte Einrichtung: I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; European Reference Network on Hepatological Diseases (ERN R…. Hauptthemen laut MEDLINE: Mycophenolic Acid, Hepatitis, Autoimmune, Immunosuppressive Agents, Azathioprine. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Birmingham Biomedical Research Centre, Hamburgische Stiftung für Wissenschaften Entwicklung und Kultur Helmut und Hannelore Greve, Royal College of Physicians.
Abstract (Originalsprache)
BACKGROUND & AIMS: Azathioprine (AZA) and corticosteroids are the recommended standard therapy for autoimmune hepatitis (AIH); however, a significant proportion of patients discontinue AZA due to intolerance. Although guidelines propose 6-mercaptopurine (6-MP) and mycophenolate mofetil (MMF) as alternatives, there is a lack of data on 6-MP and no comparative studies in AIH. We aimed to compare the efficacy and safety of 6-MP and MMF as second-line therapies in patients intolerant to AZA. METHODS: This multicenter retrospective cohort study involved patients with AIH from 11 tertiary care centers across Europe and Canada who were intolerant to AZA and subsequently switched to either 6-MP or MMF as second-line interventions. Data on biochemical response, adverse effects, and treatment duration of second-line therapies were collected and analyzed, incorporating propensity score matching to validate the biochemical response. RESULTS: We included 211 patients with AIH (81% female; median age, 54 years; interquartile range [IQR], 39-63 years) with a median follow-up of 60 months (IQR, 31-105 months). MMF was better tolerated than 6-MP (89% vs 67%; P < .001). Among patients who continued second-line treatment, no statistically significant difference in complete biochemical response rates was observed between 6-MP and MMF (61% and 66%, respectively, at the last follow-up). CONCLUSIONS: Both 6-MP and MMF were capable of maintaining biochemical response in patients with AIH who were intolerant to AZA, with no clear evidence of inferiority of either treatment. Although MMF was generally better tolerated, 6-MP may present a safe and effective treatment option in women of reproductive age. In addition, therapy with 6-MP enables clinicians to monitor drug metabolite levels, titrate dosages, and monitor adherence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany. Electronic address: l.horst@uke.de.
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany; Liver Disease Unit, Internal Medicine Department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra…
- Department of Gastroenterology, Harran University Hospital, Şanliurfa, Turkey.
- Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases Group, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Santander, Spain.
- I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.
Förderung
- Birmingham Biomedical Research Centre
- Hamburgische Stiftung für Wissenschaften Entwicklung und Kultur Helmut und Hannelore Greve
- Royal College of Physicians
- Sir Jules Thorn Charitable Trust
Zitieren
APA
Less-Horst, L. J., Fierenz, A., Canhão, B., Efe, C., Díaz-González, Á., Hartl, J., Hübener, S., Kovats, P. J., Liberal, R., Lohse, A. W., Londoño, M. C., Lytvyak, E., Macedo, G., Madaleno, J., Muñoz, B. M., Montano-Loza, A. J., Morris, S. M., Pallotta, D. P., Papp, M., …, & Schramm, C. (2026). 6-Mercaptopurine vs Mycophenolate Mofetil in Autoimmune Hepatitis and Azathioprine Intolerance: A Multicenter Study. Clinical Gastroenterology and Hepatology, 24(11), 3044-3054. https://doi.org/10.1016/j.cgh.2026.01.010
Vancouver
Less-Horst LJ, Fierenz A, Canhão B, Efe C, Díaz-González Á, Hartl J, et al. 6-Mercaptopurine vs Mycophenolate Mofetil in Autoimmune Hepatitis and Azathioprine Intolerance: A Multicenter Study. Clinical Gastroenterology and Hepatology. 2026;24(11):3044-3054. doi:10.1016/j.cgh.2026.01.010
BibTeX
@article{LessHorst2026,
author = {Less-Horst, Ludwig Jesse and Fierenz, Alexander and Canhão, Bernardo and Efe, Cumali and Díaz-González, Álvaro and Hartl, Johannes and Hübener, Sina and Kovats, Patricia Julianna and Liberal, Rodrigo and Lohse, Ansgar Wilhelm and Londoño, Maria-Carlota and Lytvyak, Ellina and Macedo, Guilherme and Madaleno, João and Muñoz, Beatriz Mateos and Montano-Loza, Aldo J and Morris, Sean M and Pallotta, Dante Pio and Papp, Mária and Sebode, Marcial and Trivedi, Palak Jitendrakumar and Oo, Ye Htun and Schramm, Christoph},
title = {6-Mercaptopurine vs Mycophenolate Mofetil in Autoimmune Hepatitis and Azathioprine Intolerance: A Multicenter Study},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {11},
pages = {3044--3054},
doi = {10.1016/j.cgh.2026.01.010}
}
EUVIMED